311 related articles for article (PubMed ID: 15795695)
1. A two-phased population epidemiological study of the safety of thimerosal-containing vaccines: a follow-up analysis.
Geier DA; Geier MR
Med Sci Monit; 2005 Apr; 11(4):CR160-70. PubMed ID: 15795695
[TBL] [Abstract][Full Text] [Related]
2. Neurodevelopmental disorders following thimerosal-containing childhood immunizations: a follow-up analysis.
Geier D; Geier MR
Int J Toxicol; 2004; 23(6):369-76. PubMed ID: 15764492
[TBL] [Abstract][Full Text] [Related]
3. A meta-analysis epidemiological assessment of neurodevelopmental disorders following vaccines administered from 1994 through 2000 in the United States.
Geier DA; Geier MR
Neuro Endocrinol Lett; 2006 Aug; 27(4):401-13. PubMed ID: 16807526
[TBL] [Abstract][Full Text] [Related]
4. An evaluation of the effects of thimerosal on neurodevelopmental disorders reported following DTP and Hib vaccines in comparison to DTPH vaccine in the United States.
Geier DA; Geier MR
J Toxicol Environ Health A; 2006 Aug; 69(15):1481-95. PubMed ID: 16766480
[TBL] [Abstract][Full Text] [Related]
5. An assessment of downward trends in neurodevelopmental disorders in the United States following removal of Thimerosal from childhood vaccines.
Geier DA; Geier MR
Med Sci Monit; 2006 Jun; 12(6):CR231-9. PubMed ID: 16733480
[TBL] [Abstract][Full Text] [Related]
6. Safety of thimerosal-containing vaccines: a two-phased study of computerized health maintenance organization databases.
Verstraeten T; Davis RL; DeStefano F; Lieu TA; Rhodes PH; Black SB; Shinefield H; Chen RT;
Pediatrics; 2003 Nov; 112(5):1039-48. PubMed ID: 14595043
[TBL] [Abstract][Full Text] [Related]
7. Thimerosal exposure in infants and neurodevelopmental disorders: an assessment of computerized medical records in the Vaccine Safety Datalink.
Young HA; Geier DA; Geier MR
J Neurol Sci; 2008 Aug; 271(1-2):110-8. PubMed ID: 18482737
[TBL] [Abstract][Full Text] [Related]
8. Thimerosal exposure in infants and developmental disorders: a retrospective cohort study in the United kingdom does not support a causal association.
Andrews N; Miller E; Grant A; Stowe J; Osborne V; Taylor B
Pediatrics; 2004 Sep; 114(3):584-91. PubMed ID: 15342825
[TBL] [Abstract][Full Text] [Related]
9. [Lack of association between thimerosal-containing vaccines and autism].
Mrozek-Budzyn D; Majewska R; Kiełtyka A; Augustyniak M
Przegl Epidemiol; 2011; 65(3):491-5. PubMed ID: 22184954
[TBL] [Abstract][Full Text] [Related]
10. An assessment of the impact of thimerosal on childhood neurodevelopmental disorders.
Geier DA; Geier MR
Pediatr Rehabil; 2003; 6(2):97-102. PubMed ID: 14534046
[TBL] [Abstract][Full Text] [Related]
11. A comparative evaluation of the effects of MMR immunization and mercury doses from thimerosal-containing childhood vaccines on the population prevalence of autism.
Geier DA; Geier MR
Med Sci Monit; 2004 Mar; 10(3):PI33-9. PubMed ID: 14976450
[TBL] [Abstract][Full Text] [Related]
12. Thimerosal-containing vaccines and autistic spectrum disorder: a critical review of published original data.
Parker SK; Schwartz B; Todd J; Pickering LK
Pediatrics; 2004 Sep; 114(3):793-804. PubMed ID: 15342856
[TBL] [Abstract][Full Text] [Related]
13. Thimerosal exposure in infants and developmental disorders: a prospective cohort study in the United kingdom does not support a causal association.
Heron J; Golding J;
Pediatrics; 2004 Sep; 114(3):577-83. PubMed ID: 15342824
[TBL] [Abstract][Full Text] [Related]
14. Neurodevelopmental disorders after thimerosal-containing vaccines: a brief communication.
Geier MR; Geier DA
Exp Biol Med (Maywood); 2003 Jun; 228(6):660-4. PubMed ID: 12773696
[TBL] [Abstract][Full Text] [Related]
15. Pertussis vaccine effectiveness among children 6 to 59 months of age in the United States, 1998-2001.
Bisgard KM; Rhodes P; Connelly BL; Bi D; Hahn C; Patrick S; Glodé MP; Ehresmann KR;
Pediatrics; 2005 Aug; 116(2):e285-94. PubMed ID: 16061582
[TBL] [Abstract][Full Text] [Related]
16. Neurodevelopmental disorders, maternal Rh-negativity, and Rho(D) immune globulins: a multi-center assessment.
Geier DA; Mumper E; Gladfelter B; Coleman L; Geier MR
Neuro Endocrinol Lett; 2008 Apr; 29(2):272-80. PubMed ID: 18404135
[TBL] [Abstract][Full Text] [Related]
17. Assessment of nine candidate DTP-vaccines with reduced amount of antigen and/or without adjuvant as a fourth (booster-) dose in the second year of life.
Knuf M; Habermehl P; Faber J; Bock HL; Sänger R; Bogaerts H; Clemens R; Schuind A; du Prel JB; Schmitt HJ
Vaccine; 2006 Jul; 24(27-28):5627-36. PubMed ID: 16740348
[TBL] [Abstract][Full Text] [Related]
18. [Mercury in vaccines].
Hessel L
Bull Acad Natl Med; 2003; 187(8):1501-10. PubMed ID: 15146581
[TBL] [Abstract][Full Text] [Related]
19. Early thimerosal exposure and neuropsychological outcomes at 7 to 10 years.
Thompson WW; Price C; Goodson B; Shay DK; Benson P; Hinrichsen VL; Lewis E; Eriksen E; Ray P; Marcy SM; Dunn J; Jackson LA; Lieu TA; Black S; Stewart G; Weintraub ES; Davis RL; DeStefano F;
N Engl J Med; 2007 Sep; 357(13):1281-92. PubMed ID: 17898097
[TBL] [Abstract][Full Text] [Related]
20. An evaluation of serious neurological disorders following immunization: a comparison of whole-cell pertussis and acellular pertussis vaccines.
Geier DA; Geier MR
Brain Dev; 2004 Aug; 26(5):296-300. PubMed ID: 15165669
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
